Gyre Therapeutics, Inc. Cash and Restricted Cash
Gyre Therapeutics, Inc. (GYRE) had Cash and Restricted Cash of $126.72 million as of 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-05-03
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $126.72M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.80M.
- 2017-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27.39M.
- 2016-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $29.86M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-03-31 | $126.72M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $19.80M 10-Q · filed 2018-05-03 |
| 2017-03-31 | $27.39M 10-Q · filed 2018-05-03 |
| 2016-12-31 | $29.86M 10-Q · filed 2018-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |